Skip to main content

Table 1 Values, notes, and sources for variables used to predict HIV infection reduction savings

From: Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility

Variable Value Note Source
Proportion of PWID HIV− (I) 82.30%   Mehta [6]
Number of needles in circulation (N) 1,600,000 Increased by 33% due to additional syringe sources Hunt and Parker [81];German et al. [82]
Rate of needle sharing (s) 2.8% Percent of injections with a needle already used by another person Park et al. [83]
Percentage of needles not bleached (d) 100%   Bluthenthal et al. [84]
Proportion of PWID HIV+ (q) 17.70%   Mehta [6]
Probability of HIV infections from a single injection (t) 0.67%   Kaplan and O’Keefe [85]; Kwon et al. [86]
Number of sharing partners (m) 1.2 Per injection: ratio of receptive to distributive sharing Park et al. [83]
SIF client reduction in needle sharing (n) 70% From Insite Kerr et al. [40]
Number of SIF clients (N) 2100 Approximate monthly unique Insite injection room clients Maynard [33]
PWID Population (T) 20,950 Adjusted by authors from Baltimore MSA to City using race census data Tempalski et al. [87]
Lifetime HIV treatment cost $402,000 National data CDC [88]